Patiromer for Patients with Heart Failure at Risk of Hyperkalemia: CARE-HK in HF Registry
In contemporary clinical practice, patiromer was associated with reducing sK+ but rates of RASi/MRA optimization remain low. Overcoming clinical inertia, including the addition of patiromer when appropriate, is required to optimize RASi/MRA therapy in patients with HF at high risk of HK.
Authors
- Ellie Kelepouris
- C. Brandes
- Khaja Chinnakondepalli (ORCID: https://orcid.org/0000-0002-7405-8614)
- Tibor Kempf (ORCID: https://orcid.org/0000-0001-6901-8442)
- Victoria Donachie
- Andrew J. Sauer
- Omar Cantu Martinez
- Giuseppe Rosano
- Javed Butler
- John G. Cleland
- Nihar Desai
- Martin Schulz
- Stephen J. Greene
- Stefan D. Anker
- Biykem Bozkurt
- Diederick E. Grobbee
Institutions
- Yale New Haven Hospital (US)
- Vita-Salute San Raffaele University (IT)
- Duke University (US)
- Baylor College of Medicine (US)
- Utrecht University (NL)
- San Raffaele University of Rome (IT)
- University Medical Center Utrecht (NL)
- University of Mississippi (US)
- Clinical Research Institute (US)
- Vifor Pharma (Switzerland) (CH)
- Klinikum Braunschweig (DE)
- Federal Union of German Associations of Pharmacists (DE)
- German Centre for Cardiovascular Research (DE)
- Saint Luke's Hospital (US)
- Duke University Hospital (US)
- Baylor Scott & White Health (US)
- University of Missouri–Kansas City (US)
- University of Glasgow (GB)
- University of Pennsylvania (US)
Publication Details
- Journal
- Journal of Cardiac Failure
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.cardfail.2026.03.025
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00